Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome—A retrospective observational study

Nephrotic syndrome (NS) is associated with increased risk of venous thromboembolism (VTE). Guidelines suggest prophylactic anticoagulants to patients with high risk of thrombosis and low risk of bleeding, but the evidence behind this is poor. This study aims to investigate the effectiveness and risk...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2021-07, Vol.16 (7), p.e0255009-e0255009
Main Authors: Welander, Frida, Holmberg, Henrik, Dimény, Emöke, Jansson, Ulf, Själander, Anders
Format: Article
Language:English
Subjects:
Albumin
Albumins
Anticoagulants
Anticoagulants (Medicine)
Biology and Life Sciences
Biopsy
Bleeding
Care and treatment
Clinical medicine
Complications and side effects
Creatinine
Diabetes
Disease prevention
Drug dosages
Health risks
Kidney diseases
Kidney transplants
Laboratories
Medical records
Medicine
Medicine and Health Sciences
Nephrology
Nephrotic syndrome
Observational studies
Patient outcomes
Patients
Public health
Remission (Medicine)
Renal replacement therapy
Risk analysis
Risk factors
Statistical analysis
Thromboembolism
Thrombosis
Urine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c707t-ca9d90f33400a0e8ec16d589863f7a68bcead2db05bcc894dc3ea414b615403b3
cites cdi_FETCH-LOGICAL-c707t-ca9d90f33400a0e8ec16d589863f7a68bcead2db05bcc894dc3ea414b615403b3
container_end_page e0255009
container_issue 7
container_start_page e0255009
container_title PloS one
container_volume 16
creator Welander, Frida
Holmberg, Henrik
Dimény, Emöke
Jansson, Ulf
Själander, Anders
description Nephrotic syndrome (NS) is associated with increased risk of venous thromboembolism (VTE). Guidelines suggest prophylactic anticoagulants to patients with high risk of thrombosis and low risk of bleeding, but the evidence behind this is poor. This study aims to investigate the effectiveness and risks of prophylactic anticoagulants (PAC) and investigate risk factors for VTE and bleeding in NS. A retrospective medical records study including adults with NS, biopsy proven glomerular disease in the county of Västernorrland, Sweden. Outcomes were VTE, bleeding and death. Patients divided into PAC- and no PAC group were compared using Fisher's exact test. Patient time was divided into serum/plasma(S/P)-albumin intervals (
doi_str_mv 10.1371/journal.pone.0255009
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2555945487</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A669894116</galeid><doaj_id>oai_doaj_org_article_56db623d1a9b4067bd43a63ec7d5d371</doaj_id><sourcerecordid>A669894116</sourcerecordid><originalsourceid>FETCH-LOGICAL-c707t-ca9d90f33400a0e8ec16d589863f7a68bcead2db05bcc894dc3ea414b615403b3</originalsourceid><addsrcrecordid>eNqNk92K1DAUx4so7jr6BoIFQfRixqRp0-ZGGNavgYUVP_Y2pMnptEPb1KSdde688wV8Qp_E050qW9kLKU1C-jv_9PzPSRA8pmRFWUpf7uzgWlWvOtvCikRJQoi4E5xSwaIljwi7e2N9EjzwfkdIwjLO7wcnLGZUCJGdBj8-ONuVh1rpvtKhanG0ajvUuPJhb8POwR7aPsTBDrhTOtvkFvCtK9-EVRt2qq9gpK-qvgxb6BAZtfyhNQjDr-8_16GD3lnfAZ6yh9DmHtwe4ywmEPp-MIeHwb1C1R4eTfMi-PL2zeez98vzi3ebs_X5Uqck7ZdaCSNIwVhMiCKQgabcJJnIOCtSxbNcgzKRyUmSa52J2GgGKqZxzmkSE5azRfDkqNvV1svJQy_RvkTESZylSGyOhLFqJztXNcodpFWVvN6wbiuVwwRrkAk3OY-YoUrkMeFpbmKmOAOdmsRgjVBredTyV9AN-UztdXW5vlYbmkFSQSMukH81_d2QN2A0-upUPQubf2mrUm7tXmaMZhFWdRE8nwSc_TqA72VTeQ011hOwfmOeHHuApRGiT_9Bb3djorYKE67awuK5ehSVa84FWkwpR2p1C4WPgQYbqoWiwv1ZwItZADI9fOu3avBebj59_H_24nLOPrvBlqDqvvS2HsZW83MwPoIa-9I7KP6aTIkc79cfN-R4v-R0v9hvm2gcWQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2555945487</pqid></control><display><type>article</type><title>Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome—A retrospective observational study</title><source>PubMed Central Free</source><source>Publicly Available Content Database</source><creator>Welander, Frida ; Holmberg, Henrik ; Dimény, Emöke ; Jansson, Ulf ; Själander, Anders</creator><contributor>ten Cate, Hugo</contributor><creatorcontrib>Welander, Frida ; Holmberg, Henrik ; Dimény, Emöke ; Jansson, Ulf ; Själander, Anders ; ten Cate, Hugo</creatorcontrib><description>Nephrotic syndrome (NS) is associated with increased risk of venous thromboembolism (VTE). Guidelines suggest prophylactic anticoagulants to patients with high risk of thrombosis and low risk of bleeding, but the evidence behind this is poor. This study aims to investigate the effectiveness and risks of prophylactic anticoagulants (PAC) and investigate risk factors for VTE and bleeding in NS. A retrospective medical records study including adults with NS, biopsy proven glomerular disease in the county of Västernorrland, Sweden. Outcomes were VTE, bleeding and death. Patients divided into PAC- and no PAC group were compared using Fisher's exact test. Patient time was divided into serum/plasma(S/P)-albumin intervals (&lt;20g/L and [greater than or equal to]20g/L) and VTE- and bleeding rates were calculated. In 95 included NS patients (PAC = 40, no PAC = 55), 7 VTE (7.4%) and 17 bleedings (18%) were found. Outcomes didn't differ significantly between the PAC and no PAC group. Time with S/P-albumin 20g/L. Duration of severe hypoalbuminemia (S/P-albumin &lt;20g/L) in NS is a risk factor for both VTE and bleeding. There is a need for randomized controlled studies regarding the benefit of PAC in NS as well as risk factors of thrombosis and bleeding in NS.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0255009</identifier><identifier>PMID: 34319998</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Albumin ; Albumins ; Anticoagulants ; Anticoagulants (Medicine) ; Biology and Life Sciences ; Biopsy ; Bleeding ; Care and treatment ; Clinical medicine ; Complications and side effects ; Creatinine ; Diabetes ; Disease prevention ; Drug dosages ; Health risks ; Kidney diseases ; Kidney transplants ; Laboratories ; Medical records ; Medicine ; Medicine and Health Sciences ; Nephrology ; Nephrotic syndrome ; Observational studies ; Patient outcomes ; Patients ; Public health ; Remission (Medicine) ; Renal replacement therapy ; Risk analysis ; Risk factors ; Statistical analysis ; Thromboembolism ; Thrombosis ; Urine</subject><ispartof>PloS one, 2021-07, Vol.16 (7), p.e0255009-e0255009</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Welander et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Welander et al 2021 Welander et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c707t-ca9d90f33400a0e8ec16d589863f7a68bcead2db05bcc894dc3ea414b615403b3</citedby><cites>FETCH-LOGICAL-c707t-ca9d90f33400a0e8ec16d589863f7a68bcead2db05bcc894dc3ea414b615403b3</cites><orcidid>0000-0003-1111-7215 ; 0000-0001-6206-3099</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2555945487/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2555945487?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-191269$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><contributor>ten Cate, Hugo</contributor><creatorcontrib>Welander, Frida</creatorcontrib><creatorcontrib>Holmberg, Henrik</creatorcontrib><creatorcontrib>Dimény, Emöke</creatorcontrib><creatorcontrib>Jansson, Ulf</creatorcontrib><creatorcontrib>Själander, Anders</creatorcontrib><title>Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome—A retrospective observational study</title><title>PloS one</title><description>Nephrotic syndrome (NS) is associated with increased risk of venous thromboembolism (VTE). Guidelines suggest prophylactic anticoagulants to patients with high risk of thrombosis and low risk of bleeding, but the evidence behind this is poor. This study aims to investigate the effectiveness and risks of prophylactic anticoagulants (PAC) and investigate risk factors for VTE and bleeding in NS. A retrospective medical records study including adults with NS, biopsy proven glomerular disease in the county of Västernorrland, Sweden. Outcomes were VTE, bleeding and death. Patients divided into PAC- and no PAC group were compared using Fisher's exact test. Patient time was divided into serum/plasma(S/P)-albumin intervals (&lt;20g/L and [greater than or equal to]20g/L) and VTE- and bleeding rates were calculated. In 95 included NS patients (PAC = 40, no PAC = 55), 7 VTE (7.4%) and 17 bleedings (18%) were found. Outcomes didn't differ significantly between the PAC and no PAC group. Time with S/P-albumin 20g/L. Duration of severe hypoalbuminemia (S/P-albumin &lt;20g/L) in NS is a risk factor for both VTE and bleeding. There is a need for randomized controlled studies regarding the benefit of PAC in NS as well as risk factors of thrombosis and bleeding in NS.</description><subject>Albumin</subject><subject>Albumins</subject><subject>Anticoagulants</subject><subject>Anticoagulants (Medicine)</subject><subject>Biology and Life Sciences</subject><subject>Biopsy</subject><subject>Bleeding</subject><subject>Care and treatment</subject><subject>Clinical medicine</subject><subject>Complications and side effects</subject><subject>Creatinine</subject><subject>Diabetes</subject><subject>Disease prevention</subject><subject>Drug dosages</subject><subject>Health risks</subject><subject>Kidney diseases</subject><subject>Kidney transplants</subject><subject>Laboratories</subject><subject>Medical records</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Nephrology</subject><subject>Nephrotic syndrome</subject><subject>Observational studies</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Public health</subject><subject>Remission (Medicine)</subject><subject>Renal replacement therapy</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Statistical analysis</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>Urine</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNk92K1DAUx4so7jr6BoIFQfRixqRp0-ZGGNavgYUVP_Y2pMnptEPb1KSdde688wV8Qp_E050qW9kLKU1C-jv_9PzPSRA8pmRFWUpf7uzgWlWvOtvCikRJQoi4E5xSwaIljwi7e2N9EjzwfkdIwjLO7wcnLGZUCJGdBj8-ONuVh1rpvtKhanG0ajvUuPJhb8POwR7aPsTBDrhTOtvkFvCtK9-EVRt2qq9gpK-qvgxb6BAZtfyhNQjDr-8_16GD3lnfAZ6yh9DmHtwe4ywmEPp-MIeHwb1C1R4eTfMi-PL2zeez98vzi3ebs_X5Uqck7ZdaCSNIwVhMiCKQgabcJJnIOCtSxbNcgzKRyUmSa52J2GgGKqZxzmkSE5azRfDkqNvV1svJQy_RvkTESZylSGyOhLFqJztXNcodpFWVvN6wbiuVwwRrkAk3OY-YoUrkMeFpbmKmOAOdmsRgjVBredTyV9AN-UztdXW5vlYbmkFSQSMukH81_d2QN2A0-upUPQubf2mrUm7tXmaMZhFWdRE8nwSc_TqA72VTeQ011hOwfmOeHHuApRGiT_9Bb3djorYKE67awuK5ehSVa84FWkwpR2p1C4WPgQYbqoWiwv1ZwItZADI9fOu3avBebj59_H_24nLOPrvBlqDqvvS2HsZW83MwPoIa-9I7KP6aTIkc79cfN-R4v-R0v9hvm2gcWQ</recordid><startdate>20210728</startdate><enddate>20210728</enddate><creator>Welander, Frida</creator><creator>Holmberg, Henrik</creator><creator>Dimény, Emöke</creator><creator>Jansson, Ulf</creator><creator>Själander, Anders</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>ADHXS</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>D93</scope><scope>ZZAVC</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-1111-7215</orcidid><orcidid>https://orcid.org/0000-0001-6206-3099</orcidid></search><sort><creationdate>20210728</creationdate><title>Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome—A retrospective observational study</title><author>Welander, Frida ; Holmberg, Henrik ; Dimény, Emöke ; Jansson, Ulf ; Själander, Anders</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c707t-ca9d90f33400a0e8ec16d589863f7a68bcead2db05bcc894dc3ea414b615403b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Albumin</topic><topic>Albumins</topic><topic>Anticoagulants</topic><topic>Anticoagulants (Medicine)</topic><topic>Biology and Life Sciences</topic><topic>Biopsy</topic><topic>Bleeding</topic><topic>Care and treatment</topic><topic>Clinical medicine</topic><topic>Complications and side effects</topic><topic>Creatinine</topic><topic>Diabetes</topic><topic>Disease prevention</topic><topic>Drug dosages</topic><topic>Health risks</topic><topic>Kidney diseases</topic><topic>Kidney transplants</topic><topic>Laboratories</topic><topic>Medical records</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Nephrology</topic><topic>Nephrotic syndrome</topic><topic>Observational studies</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Public health</topic><topic>Remission (Medicine)</topic><topic>Renal replacement therapy</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Statistical analysis</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Welander, Frida</creatorcontrib><creatorcontrib>Holmberg, Henrik</creatorcontrib><creatorcontrib>Dimény, Emöke</creatorcontrib><creatorcontrib>Jansson, Ulf</creatorcontrib><creatorcontrib>Själander, Anders</creatorcontrib><collection>CrossRef</collection><collection>Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Umeå universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Umeå universitet</collection><collection>SwePub Articles full text</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Welander, Frida</au><au>Holmberg, Henrik</au><au>Dimény, Emöke</au><au>Jansson, Ulf</au><au>Själander, Anders</au><au>ten Cate, Hugo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome—A retrospective observational study</atitle><jtitle>PloS one</jtitle><date>2021-07-28</date><risdate>2021</risdate><volume>16</volume><issue>7</issue><spage>e0255009</spage><epage>e0255009</epage><pages>e0255009-e0255009</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Nephrotic syndrome (NS) is associated with increased risk of venous thromboembolism (VTE). Guidelines suggest prophylactic anticoagulants to patients with high risk of thrombosis and low risk of bleeding, but the evidence behind this is poor. This study aims to investigate the effectiveness and risks of prophylactic anticoagulants (PAC) and investigate risk factors for VTE and bleeding in NS. A retrospective medical records study including adults with NS, biopsy proven glomerular disease in the county of Västernorrland, Sweden. Outcomes were VTE, bleeding and death. Patients divided into PAC- and no PAC group were compared using Fisher's exact test. Patient time was divided into serum/plasma(S/P)-albumin intervals (&lt;20g/L and [greater than or equal to]20g/L) and VTE- and bleeding rates were calculated. In 95 included NS patients (PAC = 40, no PAC = 55), 7 VTE (7.4%) and 17 bleedings (18%) were found. Outcomes didn't differ significantly between the PAC and no PAC group. Time with S/P-albumin 20g/L. Duration of severe hypoalbuminemia (S/P-albumin &lt;20g/L) in NS is a risk factor for both VTE and bleeding. There is a need for randomized controlled studies regarding the benefit of PAC in NS as well as risk factors of thrombosis and bleeding in NS.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><pmid>34319998</pmid><doi>10.1371/journal.pone.0255009</doi><orcidid>https://orcid.org/0000-0003-1111-7215</orcidid><orcidid>https://orcid.org/0000-0001-6206-3099</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2021-07, Vol.16 (7), p.e0255009-e0255009
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_2555945487
source PubMed Central Free; Publicly Available Content Database
subjects Albumin
Albumins
Anticoagulants
Anticoagulants (Medicine)
Biology and Life Sciences
Biopsy
Bleeding
Care and treatment
Clinical medicine
Complications and side effects
Creatinine
Diabetes
Disease prevention
Drug dosages
Health risks
Kidney diseases
Kidney transplants
Laboratories
Medical records
Medicine
Medicine and Health Sciences
Nephrology
Nephrotic syndrome
Observational studies
Patient outcomes
Patients
Public health
Remission (Medicine)
Renal replacement therapy
Risk analysis
Risk factors
Statistical analysis
Thromboembolism
Thrombosis
Urine
title Prophylactic anticoagulants to prevent venous thromboembolism in patients with nephrotic syndrome—A retrospective observational study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T22%3A45%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prophylactic%20anticoagulants%20to%20prevent%20venous%20thromboembolism%20in%20patients%20with%20nephrotic%20syndrome%E2%80%94A%20retrospective%20observational%20study&rft.jtitle=PloS%20one&rft.au=Welander,%20Frida&rft.date=2021-07-28&rft.volume=16&rft.issue=7&rft.spage=e0255009&rft.epage=e0255009&rft.pages=e0255009-e0255009&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0255009&rft_dat=%3Cgale_plos_%3EA669894116%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c707t-ca9d90f33400a0e8ec16d589863f7a68bcead2db05bcc894dc3ea414b615403b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2555945487&rft_id=info:pmid/34319998&rft_galeid=A669894116&rfr_iscdi=true